| Disaggregation of Revenue |
The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three and nine-month periods ended September 25, 2026 and September 26, 2025 ($ in millions). Sales taxes and other usage-based taxes collected from customers are excluded from revenue. | | | | | | | | | | | | | | | | | | | | | | | | | Biotechnology | | Life Sciences | | Diagnostics | | Total | | For the Three-Month Period Ended September 25, 2026: | | | | | | | | Geographical region: | | | | | | | | North America(a) | $ | 550 | | | $ | 751 | | | $ | 1,439 | | | $ | 2,740 | | | Western Europe | 605 | | | 411 | | | 474 | | | 1,490 | | Other developed markets(b) | 58 | | | 132 | | | 108 | | | 298 | | High-growth markets(c) | 594 | | | 571 | | | 861 | | | 2,026 | | | Total | $ | 1,807 | | | $ | 1,865 | | | $ | 2,882 | | | $ | 6,554 | | | | | | | | | | | Revenue type: | | | | | | | | | Recurring | $ | 1,584 | | | $ | 1,282 | | | $ | 2,533 | | | $ | 5,399 | | | Nonrecurring | 223 | | | 583 | | | 349 | | | 1,155 | | | Total | $ | 1,807 | | | $ | 1,865 | | | $ | 2,882 | | | $ | 6,554 | | | | | | | | | | | For the Three-Month Period Ended September 26, 2025: | | | | | | | | Geographical region: | | | | | | | | North America(a) | $ | 624 | | | $ | 728 | | | $ | 1,228 | | | $ | 2,580 | | | Western Europe | 587 | | | 392 | | | 417 | | | 1,396 | | Other developed markets(b) | 89 | | | 130 | | | 97 | | | 316 | | High-growth markets(c) | 498 | | | 542 | | | 721 | | | 1,761 | | | Total | $ | 1,798 | | | $ | 1,792 | | | $ | 2,463 | | | $ | 6,053 | | | | | | | | | | | Revenue type: | | | | | | | | | Recurring | $ | 1,590 | | | $ | 1,216 | | | $ | 2,211 | | | $ | 5,017 | | | Nonrecurring | 208 | | | 576 | | | 252 | | | 1,036 | | | Total | $ | 1,798 | | | $ | 1,792 | | | $ | 2,463 | | | $ | 6,053 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Biotechnology | | Life Sciences | | Diagnostics | | Total | | For the Nine-Month Period Ended September 25, 2026: | | | | | | | | Geographical region: | | | | | | | | North America(a) | $ | 1,657 | | | $ | 2,199 | | | $ | 3,836 | | | $ | 7,692 | | | Western Europe | 2,020 | | | 1,240 | | | 1,335 | | | 4,595 | | Other developed markets(b) | 189 | | | 399 | | | 287 | | | 875 | | High-growth markets(c) | 1,658 | | | 1,643 | | | 2,307 | | | 5,608 | | | Total | $ | 5,524 | | | $ | 5,481 | | | $ | 7,765 | | | $ | 18,770 | | | | | | | | | | | Revenue type: | | | | | | | | | Recurring | $ | 4,948 | | | $ | 3,753 | | | $ | 6,929 | | | $ | 15,630 | | | Nonrecurring | 576 | | | 1,728 | | | 836 | | | 3,140 | | | Total | $ | 5,524 | | | $ | 5,481 | | | $ | 7,765 | | | $ | 18,770 | | | | | | | | | | | For the Nine-Month Period Ended September 26, 2025: | | | | | | | | Geographical region: | | | | | | | | North America(a) | $ | 1,779 | | | $ | 2,211 | | | $ | 3,610 | | | $ | 7,600 | | | Western Europe | 1,861 | | | 1,164 | | | 1,222 | | | 4,247 | | Other developed markets(b) | 235 | | | 371 | | | 282 | | | 888 | | High-growth markets(c) | 1,385 | | | 1,503 | | | 2,107 | | | 4,995 | | | Total | $ | 5,260 | | | $ | 5,249 | | | $ | 7,221 | | | $ | 17,730 | | | | | | | | | | | Revenue type: | | | | | | | | | Recurring | $ | 4,741 | | | $ | 3,566 | | | $ | 6,496 | | | $ | 14,803 | | | Nonrecurring | 519 | | | 1,683 | | | 725 | | | 2,927 | | | Total | $ | 5,260 | | | $ | 5,249 | | | $ | 7,221 | | | $ | 17,730 | |
(a) The Company defines North America as the United States and Canada. (b) The Company defines other developed markets as all the markets of the world that are not North America, Western Europe or high-growth markets. (c) The Company defines high-growth markets as developing markets of the world experiencing accelerated growth, over extended periods, in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America (including Mexico) and Asia (with the exception of Japan, Australia and New Zealand). The Company defines developed markets as all markets of the world that are not high-growth markets.
|